Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: a dose-escalation phase I study
Experts typically use bacteriostatic water, containing 0.9% benzyl alcohol added as a preservative
aureus (p = 0.002) and a 38% increase against E
The REMAIN-1 Pivotal Cohort has completed enrollment, and the Company remains on track to randomize patients in early 2026 and deliver 6-month topline primary endpoint data and potentially file a PMA in H2 2026
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
US$ 28.32
US$ 20.73
US$ 20.46
US$ 22.07
US$ 28.62
